Since treatment with HMA results in upregulation of CD70 on leukemic stem cells from AML patients, a phase I clinical trial studied combination of HMA with the monoclonal anti-CD70 antibody cusatuzumab (NCT03030612) [25]. Here, CD70 is linked to acute myeloid leukemia.